ERAS

ERAS

Erasca Inc

Rev โ€”top 1%5Y
Hold

Erasca Inc develops therapies targeting RAS/MAPK pathway-driven cancers, focusing on RAS-mutated solid tumors. Its pipeline includes ERAS-0015, ERAS-4001, and ERAS-12, aiming to provide innovative treatments for patients with specific genetic mutations.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$962today

Score Overview

1 Year
Scoreโ€”
Net Growth-122.42%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-125.65%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-125.65%
Net Trend40%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Erasca Inc fundamental performance

Across Erasca Inc's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 122M to -$ 124M. Revenue increased in 0% of the years measured; net income in 40%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 18.58โ€”
5 Years2021-08-12
$ 19.32-3.83%
All Time2021-07-16
$ 17.436.60%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 277M$ 243M
2025$ 0.00-$ 124M$ 276M
2024$ 0.00-$ 161M$ 298M
2023$ 0.00-$ 125M$ 312M
2022$ 0.00-$ 242M$ 435M
IPO2021$ 0.00-$ 122M$ 459M

Explore beyond ERAS

You're looking at Erasca Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies